VanEck Video Gaming and eSports ETF vs Edwards Lifesciences Corporation Common Stock — how do they compare? VanEck Video Gaming and eSports ETF trades at $98.11 (market cap $248.87M), while Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 198.7× VanEck Video Gaming and eSports ETF's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | EW | |
|---|---|---|
Market Cap | $248.87M | $49.44B |
Volume | 7,078 | 3,508,027 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $95.18 |
52-Week Low | $85.25 | $72.65 |
Typical Hold Time | 65 Days | — |
Enterprise Value | — | $45.90B |
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.32, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $97 and resistance at $98. Financial ratios are unavailable in the provided data, limiting fundamental insight. No recent news is available to drive sentiment.
The outlook is mixed: technicals suggest upward momentum, but the absence of fundamental data and recent news creates uncertainty. Risks include market volatility and lack of visibility on financial health. Investors need updated earnings and guidance for a clearer investment case.
No Aura AI signal available yet.
Trailing returns across standard periods
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →